The outcome was, however, as expected, more favorable in patients diagnosed with NPM1-mutated AML devoid of karyotype aberrations or FLT3-ITD mutations, where 67% of patients (n = 14) were alive and relapse-free at 2 years. The gene discussed is FLT3; the disease is acute myeloid leukemia.